flecainide has been researched along with Embryopathies in 52 studies
Flecainide: A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.
flecainide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).
| Excerpt | Relevance | Reference |
|---|---|---|
| "An infant with intrauterine supraventricular tachycardia and fetal hydrops, successfully treated with administration of flecainide acetate to the mother had conjugated hyperbilirubinemia shortly after birth." | 7.69 | Conjugated hyperbilirubinemia in a newborn infant after maternal (transplacental) treatment with flecainide acetate for fetal tachycardia and fetal hydrops. ( Carlson, DE; Cocjin, J; Rosenthal, P; Santulli, TV; Vanderhal, AL, 1995) |
| "Fourteen mothers were treated with flecainide for fetal atrial tachycardias associated with intrauterine cardiac failure." | 7.68 | Flecainide in the treatment of fetal tachycardias. ( Allan, LD; Chita, SK; Maxwell, D; Priestley, K; Sharland, GK, 1991) |
| " Flecainide appeared to be safe (no deaths with usual oral dosing, < 1% serious proarrhythmia) and effective (73% to 100% control, depending on mechanism) in children with supraventricular tachycardia." | 6.38 | Flecainide acetate for treatment of tachyarrhythmias in children: review of world literature on efficacy, safety, and dosing. ( Garson, A; Perry, JC, 1992) |
| "We performed a systematic review and meta-analysis to compare digoxin, flecainide, or sotalol as first-line therapy for fetal tachycardia." | 4.95 | Transplacental treatment of fetal tachycardia: A systematic review and meta-analysis. ( Frommelt, MA; Hill, GD; Kovach, JR; Saudek, DE; Singh, AK; Wehrheim, K, 2017) |
| " In the case of atrial flutters the pregnant woman is treated with sotalol administered orally and, if no sinus rhythm is obtained nor a reduced ventricular rhythm occurs, subsequently with digoxin." | 4.81 | [Protocols for the treatment of supraventricular tachycardias in the fetus]. ( Ambachtsheer, EB; Meijboom, EJ; Oudijk, MA; Stoutenbeek, P, 2001) |
| "High-dose flecainide and digoxin combination offers effective treatment strategy in fetuses with hydrops and tachyarrhythmia with favourable outcomes." | 4.12 | Favourable outcome for hydrops or cardiac failure associated with fetal tachyarrhythmia: a 20-year review. ( Beattie, RB; Tunca Sahin, G; Uzun, O, 2022) |
| "Flecainide is an effective therapy for supraventricular tachycardias in a twin pregnancy." | 3.74 | Diagnosis, treatment, observation and outcome of fetal supraventricular tachycardia in a twin pregnancy. ( Gronemeyer, D; Hatzmann, W; Reinhard, J; Schiermeier, S; van Leeuwen, P, 2008) |
| "An infant with intrauterine supraventricular tachycardia and fetal hydrops, successfully treated with administration of flecainide acetate to the mother had conjugated hyperbilirubinemia shortly after birth." | 3.69 | Conjugated hyperbilirubinemia in a newborn infant after maternal (transplacental) treatment with flecainide acetate for fetal tachycardia and fetal hydrops. ( Carlson, DE; Cocjin, J; Rosenthal, P; Santulli, TV; Vanderhal, AL, 1995) |
| "We report a case of fetal supraventricular tachycardia with intra uterine cardiac failure, treated with oral administration of flecainide acetate (Flecaine) to the mother." | 3.69 | [Flecaine: drug of choice for supraventricular tachycardias with anasarca. A case report]. ( Barjot, P; Febbraro, W; Hamel, P; Iselin, M; Lindet, Y; Muller, G, 1997) |
| "Fourteen mothers were treated with flecainide for fetal atrial tachycardias associated with intrauterine cardiac failure." | 3.68 | Flecainide in the treatment of fetal tachycardias. ( Allan, LD; Chita, SK; Maxwell, D; Priestley, K; Sharland, GK, 1991) |
| "Neonatal tachyarrhythmia was observed in 31." | 2.90 | Antenatal Therapy for Fetal Supraventricular Tachyarrhythmias: Multicenter Trial. ( Hagiwara, A; Hamasaki, T; Horigome, H; Ikeda, T; Inamura, N; Kato, H; Katsuragi, S; Kawataki, M; Maeno, Y; Miyoshi, T; Nii, M; Sago, H; Sakaguchi, H; Shimizu, W; Shiraishi, I; Taketazu, M; Ueda, K; Yamamoto, H; Yasukochi, S; Yoda, H, 2019) |
| "Long QT syndrome was identified postnatally on the electrocardiogram, and was confirmed by genetic testing which showed a mutation in the KCNH2 gene (p." | 2.45 | Fetal ventricular tachycardia secondary to long QT syndrome treated with maternal intravenous magnesium: case report and review of the literature. ( Gill, H; Maxwell, D; Rosenthal, E; Simpson, JM, 2009) |
| " Flecainide appeared to be safe (no deaths with usual oral dosing, < 1% serious proarrhythmia) and effective (73% to 100% control, depending on mechanism) in children with supraventricular tachycardia." | 2.38 | Flecainide acetate for treatment of tachyarrhythmias in children: review of world literature on efficacy, safety, and dosing. ( Garson, A; Perry, JC, 1992) |
| "Fetal supraventricular tachycardia is a relatively uncommon cardiac rhythm abnormality which is often associated with adverse perinatal outcomes if untreated." | 1.62 | Management of Fetal Supraventricular Tachycardia: Case Series from a Tertiary Perinatal Cardiac Center. ( Broom, E; Gardener, G; Gooi, A; Kostner, K; Kumar, S; Lee-Tannock, A; Petersen, S; Thomas, JT; Ward, C, 2021) |
| "Hydrops was present 28 of 84 (33%)." | 1.43 | Flecainide versus digoxin for fetal supraventricular tachycardia: Comparison of two drug treatment protocols. ( Dominguez, TE; Janoušek, J; Marek, J; Škovránek, J; Sridharan, S; Sullivan, I; Tomek, V; Wolfenden, J; Yates, R, 2016) |
| "Transplacental flecainide is an established therapy for fetal supraventricular tachycardia (SVT), but there is a paucity of data regarding the dose-response relationship." | 1.40 | Correlation of maternal flecainide concentrations and therapeutic effect in fetal supraventricular tachycardia. ( Andrews, RE; Callaghan, N; Miller, O; Rosenthal, E; Sharland, GK; Simpson, JM; Vigneswaran, TV, 2014) |
| " This case report describes a novel approach to fetal cardioversion using oral maternal bolus dosing of flecainide." | 1.39 | A novel method of fetal cardioversion. ( Sanghavi, DM, 2013) |
| "Flecainide and digoxin were superior to sotalol in converting SVT to a normal rhythm and in slowing both AF and SVT to better-tolerated ventricular rates and therefore might be considered first to treat significant fetal tachyarrhythmia." | 1.37 | Comparison of transplacental treatment of fetal supraventricular tachyarrhythmias with digoxin, flecainide, and sotalol: results of a nonrandomized multicenter study. ( Api, O; Blom, NA; Carvalho, JS; Clur, SA; De Groot, E; Jaeggi, ET; Manlhiot, C; McCrindle, BW; Rammeloo, L; Ryan, G, 2011) |
| "Tachycardia was observed in 15% of cases (three cases of supraventricular tachycardia [SVT] and two cases of auricular flutter [AF])." | 1.31 | [Fetal arrhythmias: diagnosis, prognosis, treatment; apropos of 33 cases]. ( Dubos, JP; Dufour, P; Puech, F; Subtil, D; Vaast, P; Vaksmann, G; Valat, AS; Vautier-Rit, S, 2000) |
| "Flecainide use can cause the absence of accelerations and poor variability in the FHR." | 1.29 | The effect of flecainide acetate on fetal heart rate variability: a case report. ( de Jong, CL; de Vries, JI; van Geijn, HP; van Gelder-Hasker, MR, 1995) |
| "Fetal hydrops was seen in 22 patients." | 1.29 | Management outcome and follow-up of fetal tachycardia. ( Brenner, JI; Copel, JA; Kleinman, CS; Meijboom, EJ; Stoutenbeek, P; van Engelen, AD; Weijtens, O, 1994) |
| "Flecainide was effective in restoring sinus rhythm in all non-hydropic fetuses where digoxin treatment failed, and in 43 per cent of hydropic fetuses." | 1.29 | The efficacy of flecainide versus digoxin in the management of fetal supraventricular tachycardia. ( Den Hollander, NS; Frohn-Mulder, IM; Hess, J; Stewart, PA; Witsenburg, M; Wladimiroff, JW, 1995) |
| "The fetus required no further treatment in pregnancy or at follow up." | 1.28 | Intermittent fetal tachycardia and fetal hydrops. ( James, DK; Martin, R; Smoleniec, JS, 1991) |
| "Encainide was completely effective in 54% (22 of 41 study patients) and partially effective in an additional 24% (10 of 41 patients), when combined with propranolol or verapamil." | 1.27 | Encainide for resistant supraventricular tachycardia in children: follow-up report. ( Garson, A; Gothing, C; Moak, JP; Smith, RT; Strasburger, JF, 1988) |
| "In cases of non-immune hydrops fetalis caused by tachyarrhythmias, the transplacental passage of antiarrhythmic drugs may be hampered." | 1.27 | Direct intrauterine fetal treatment of fetal tachyarrhythmia with severe hydrops fetalis by antiarrhythmic drugs. ( Bald, R; Gembruch, U; Hansmann, M, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (5.77) | 18.7374 |
| 1990's | 16 (30.77) | 18.2507 |
| 2000's | 16 (30.77) | 29.6817 |
| 2010's | 14 (26.92) | 24.3611 |
| 2020's | 3 (5.77) | 2.80 |
| Authors | Studies |
|---|---|
| Tunca Sahin, G | 1 |
| Beattie, RB | 1 |
| Uzun, O | 2 |
| Broom, E | 1 |
| Thomas, JT | 1 |
| Petersen, S | 1 |
| Gooi, A | 1 |
| Ward, C | 1 |
| Gardener, G | 1 |
| Kostner, K | 1 |
| Lee-Tannock, A | 1 |
| Kumar, S | 1 |
| Miyoshi, T | 2 |
| Maeno, Y | 2 |
| Hamasaki, T | 2 |
| Inamura, N | 2 |
| Yasukochi, S | 2 |
| Kawataki, M | 2 |
| Horigome, H | 2 |
| Yoda, H | 2 |
| Taketazu, M | 2 |
| Nii, M | 2 |
| Hagiwara, A | 2 |
| Kato, H | 2 |
| Shimizu, W | 2 |
| Shiraishi, I | 2 |
| Sakaguchi, H | 2 |
| Ueda, K | 2 |
| Katsuragi, S | 2 |
| Yamamoto, H | 2 |
| Sago, H | 2 |
| Ikeda, T | 2 |
| Refaat, M | 1 |
| El Dick, J | 1 |
| Sabra, M | 1 |
| Bitar, F | 1 |
| Tayeh, C | 1 |
| Abutaqa, M | 1 |
| Arabi, M | 1 |
| Hill, GD | 1 |
| Kovach, JR | 1 |
| Saudek, DE | 1 |
| Singh, AK | 1 |
| Wehrheim, K | 1 |
| Frommelt, MA | 1 |
| Shozu, M | 1 |
| Alsaied, T | 1 |
| Baskar, S | 1 |
| Fares, M | 1 |
| Alahdab, F | 1 |
| Czosek, RJ | 1 |
| Murad, MH | 1 |
| Prokop, LJ | 1 |
| Divanovic, AA | 1 |
| Enzensberger, C | 1 |
| Kreymborg, KG | 1 |
| Valeske, K | 1 |
| Apitz, C | 1 |
| Akintürk, H | 1 |
| Schranz, D | 1 |
| Axt-Fliedner, R | 1 |
| Vigneswaran, TV | 1 |
| Callaghan, N | 1 |
| Andrews, RE | 1 |
| Miller, O | 1 |
| Rosenthal, E | 3 |
| Sharland, GK | 2 |
| Simpson, JM | 2 |
| Cuneo, BF | 1 |
| Benson, DW | 1 |
| Schmidt, JJ | 1 |
| Ramazan, L | 1 |
| Bockemeyer, C | 1 |
| Günter, HH | 1 |
| Martens-Lobenhoffer, J | 1 |
| Ganzenmüller, T | 1 |
| Bode-Böger, SM | 1 |
| Kielstein, JT | 1 |
| Van Hare, GF | 1 |
| Sridharan, S | 1 |
| Sullivan, I | 1 |
| Tomek, V | 1 |
| Wolfenden, J | 1 |
| Škovránek, J | 1 |
| Yates, R | 1 |
| Janoušek, J | 1 |
| Dominguez, TE | 1 |
| Marek, J | 1 |
| Ekiz, A | 1 |
| Kaya, B | 1 |
| Bornaun, H | 1 |
| Acar, DK | 1 |
| Avci, ME | 1 |
| Bestel, A | 1 |
| Yildirim, G | 1 |
| Van Leeuwen, P | 2 |
| Schiermeier, S | 2 |
| Hailer, B | 1 |
| Lange, S | 1 |
| Geue, D | 1 |
| Hatzmann, W | 2 |
| Grönemeyer, D | 2 |
| Reinhard, J | 1 |
| Maxwell, D | 2 |
| Gill, H | 1 |
| Jaeggi, ET | 1 |
| Carvalho, JS | 1 |
| De Groot, E | 1 |
| Api, O | 1 |
| Clur, SA | 1 |
| Rammeloo, L | 1 |
| McCrindle, BW | 1 |
| Ryan, G | 1 |
| Manlhiot, C | 1 |
| Blom, NA | 1 |
| Babaoglu, K | 1 |
| Sinha, A | 1 |
| Massias, S | 1 |
| Beattie, B | 1 |
| Sanghavi, DM | 1 |
| D'Souza, D | 1 |
| MacKenzie, WE | 1 |
| Martin, WL | 1 |
| Rasheed, A | 1 |
| Simpson, J | 1 |
| Jouannic, JM | 1 |
| Delahaye, S | 1 |
| Le Bidois, J | 1 |
| Fermont, L | 1 |
| Villain, E | 1 |
| Dommergues, M | 1 |
| Dumez, Y | 1 |
| Hall, CM | 1 |
| Ward Platt, MP | 1 |
| Malvino, E | 1 |
| Bruno, MC | 1 |
| Gallo, JP | 1 |
| Medrano, JC | 1 |
| Ferrante, D | 1 |
| Gerli, S | 1 |
| Clerici, G | 1 |
| Mattei, A | 1 |
| Di Renzo, GC | 1 |
| Campbell, JQ | 1 |
| Best, TH | 1 |
| Eswaran, H | 1 |
| Lowery, CL | 1 |
| van Gelder-Hasker, MR | 1 |
| de Jong, CL | 1 |
| de Vries, JI | 1 |
| van Geijn, HP | 1 |
| Vanderhal, AL | 1 |
| Cocjin, J | 1 |
| Santulli, TV | 1 |
| Carlson, DE | 1 |
| Rosenthal, P | 1 |
| van Engelen, AD | 1 |
| Weijtens, O | 1 |
| Brenner, JI | 1 |
| Kleinman, CS | 1 |
| Copel, JA | 1 |
| Stoutenbeek, P | 2 |
| Meijboom, EJ | 2 |
| Blanch, G | 1 |
| Walkinshaw, SA | 1 |
| Walsh, K | 1 |
| Frohn-Mulder, IM | 1 |
| Stewart, PA | 1 |
| Witsenburg, M | 1 |
| Den Hollander, NS | 1 |
| Wladimiroff, JW | 1 |
| Hess, J | 1 |
| Hamel, P | 2 |
| Febbraro, W | 1 |
| Barjot, P | 2 |
| Lindet, Y | 1 |
| Muller, G | 1 |
| Iselin, M | 1 |
| Azancot-Benisty, A | 2 |
| Areias, JC | 1 |
| Oberhänsli, I | 1 |
| Schmidt, KG | 1 |
| Tulzer, G | 1 |
| Viart, P | 1 |
| Calmelet, P | 1 |
| Maragnes, P | 1 |
| Herlicoviez, M | 1 |
| Edwards, A | 1 |
| Peek, MJ | 1 |
| Curren, J | 1 |
| Midgley, DY | 1 |
| Harding, K | 1 |
| Schmolling, J | 1 |
| Renke, K | 1 |
| Richter, O | 1 |
| Pfeiffer, K | 1 |
| Schlebusch, H | 1 |
| Höller, T | 1 |
| Vautier-Rit, S | 1 |
| Dufour, P | 1 |
| Vaksmann, G | 1 |
| Subtil, D | 1 |
| Vaast, P | 1 |
| Valat, AS | 1 |
| Dubos, JP | 1 |
| Puech, F | 1 |
| Kähler, C | 1 |
| Schleussner, E | 1 |
| Schneider, U | 1 |
| Seewald, HJ | 1 |
| Oudijk, MA | 1 |
| Ambachtsheer, EB | 1 |
| Krapp, M | 1 |
| Baschat, AA | 1 |
| Gembruch, U | 2 |
| Geipel, A | 1 |
| Germer, U | 1 |
| Jacqz-Aigrain, E | 1 |
| Guirgis, NM | 1 |
| Decrepy, A | 1 |
| Oury, JF | 1 |
| Blot, P | 1 |
| Perry, JC | 2 |
| Garson, A | 2 |
| Mills, M | 1 |
| Smoleniec, JS | 1 |
| Martin, R | 1 |
| James, DK | 1 |
| Allan, LD | 1 |
| Chita, SK | 1 |
| Priestley, K | 1 |
| Ayres, NA | 1 |
| Carpenter, RJ | 1 |
| Kofinas, AD | 1 |
| Simon, NV | 1 |
| Sagel, H | 1 |
| Lyttle, E | 1 |
| Smith, N | 1 |
| King, K | 1 |
| Wren, C | 1 |
| Hunter, S | 1 |
| Strasburger, JF | 1 |
| Smith, RT | 1 |
| Moak, JP | 1 |
| Gothing, C | 1 |
| Hansmann, M | 1 |
| Bald, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Safety Assessment for Sotalol Protocol in Outpatient Unit[NCT05418036] | Phase 4 | 110 participants (Anticipated) | Interventional | 2020-10-26 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for flecainide and Embryopathies
| Article | Year |
|---|---|
Sotalol as an effective adjunct therapy in the management of supraventricular tachycardia induced fetal hydrops fetalis.
Topics: Adult; Anti-Arrhythmia Agents; Digoxin; Drug Therapy, Combination; Female; Fetal Diseases; Flecainid | 2020 |
Transplacental treatment of fetal tachycardia: A systematic review and meta-analysis.
Topics: Anti-Arrhythmia Agents; Digoxin; Female; Fetal Diseases; Fetal Therapies; Flecainide; Humans; Pregna | 2017 |
First-Line Antiarrhythmic Transplacental Treatment for Fetal Tachyarrhythmia: A Systematic Review and Meta-Analysis.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Echocardiography; Female; Fetal Diseases; Fetal Therap | 2017 |
Fetal ventricular tachycardia secondary to long QT syndrome treated with maternal intravenous magnesium: case report and review of the literature.
Topics: Adult; Anti-Arrhythmia Agents; Female; Fetal Diseases; Flecainide; Humans; Injections, Intravenous; | 2009 |
[Protocols for the treatment of supraventricular tachycardias in the fetus].
Topics: Anti-Arrhythmia Agents; Atrial Flutter; Clinical Protocols; Digoxin; Drug Therapy, Combination; Fema | 2001 |
Flecainide acetate for treatment of tachyarrhythmias in children: review of world literature on efficacy, safety, and dosing.
Topics: Arrhythmias, Cardiac; Child; Child, Preschool; Fetal Diseases; Flecainide; Humans; Infant; Tachycard | 1992 |
3 trials available for flecainide and Embryopathies
| Article | Year |
|---|---|
Antenatal Therapy for Fetal Supraventricular Tachyarrhythmias: Multicenter Trial.
Topics: Administration, Oral; Adult; Anti-Arrhythmia Agents; Atrial Flutter; Cesarean Section; Digoxin; Fema | 2019 |
Clinical and pharmacologic study of fetal supraventricular tachyarrhythmias.
Topics: Digoxin; Drug Therapy, Combination; Fetal Diseases; Flecainide; Humans; Prospective Studies; Retrosp | 1992 |
Treatment of fetal supraventricular tachycardia with flecainide acetate after digoxin failure.
Topics: Adult; Digoxin; Female; Fetal Diseases; Flecainide; Humans; Pregnancy; Tachycardia, Supraventricular | 1991 |
43 other studies available for flecainide and Embryopathies
| Article | Year |
|---|---|
Favourable outcome for hydrops or cardiac failure associated with fetal tachyarrhythmia: a 20-year review.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cesarean Section; Digoxin; Female; Fetal Diseases; Fle | 2022 |
Management of Fetal Supraventricular Tachycardia: Case Series from a Tertiary Perinatal Cardiac Center.
Topics: Anti-Arrhythmia Agents; Female; Fetal Diseases; Flecainide; Humans; Hydrops Fetalis; Pregnancy; Retr | 2021 |
Antenatal antiarrhythmic treatment for fetal tachyarrhythmias: a study protocol for a prospective multicentre trial.
Topics: Anti-Arrhythmia Agents; Atrial Flutter; Child Development; Child, Preschool; Digoxin; Drug Therapy, | 2017 |
Management of idiopathic giant dilatation of the right atrium with subsequent atrial tachycardia.
Topics: Adult; Anti-Arrhythmia Agents; Digoxin; Echocardiography; Female; Fetal Diseases; Flecainide; Heart | 2013 |
Correlation of maternal flecainide concentrations and therapeutic effect in fetal supraventricular tachycardia.
Topics: Adult; Algorithms; Anti-Arrhythmia Agents; Dose-Response Relationship, Drug; Echocardiography; Femal | 2014 |
Use of maternal flecainide concentration in management of fetal supraventricular tachycardia: a step in the right direction.
Topics: Anti-Arrhythmia Agents; Female; Fetal Diseases; Flecainide; Humans; Pregnancy; Tachycardia, Supraven | 2014 |
Acute interstitial nephritis due to flecainide therapy in the 38(th) week of pregnancy.
Topics: Acute Disease; Acute Kidney Injury; Anti-Arrhythmia Agents; Anti-Inflammatory Agents, Non-Steroidal; | 2016 |
Flecainide vs digoxin for fetal supraventricular tachycardia: Comparison of 2 drug protocols.
Topics: Anti-Arrhythmia Agents; Digoxin; Fetal Diseases; Flecainide; Humans; Tachycardia; Tachycardia, Supra | 2016 |
Flecainide versus digoxin for fetal supraventricular tachycardia: Comparison of two drug treatment protocols.
Topics: Administration, Intravenous; Administration, Oral; Adult; Anti-Arrhythmia Agents; Clinical Protocols | 2016 |
Flecainide as first-line treatment for fetal supraventricular tachycardia.
Topics: Adult; Anti-Arrhythmia Agents; Echocardiography; Female; Fetal Diseases; Fetal Heart; Flecainide; Ge | 2018 |
Effect of prenatal antiarrhythmic treatment on cardiac function in a twin pregnancy.
Topics: Adult; Anti-Arrhythmia Agents; Diseases in Twins; Female; Fetal Diseases; Flecainide; Humans; Pregna | 2008 |
Diagnosis, treatment, observation and outcome of fetal supraventricular tachycardia in a twin pregnancy.
Topics: Adrenergic beta-Agonists; Adult; Anti-Arrhythmia Agents; Echocardiography; Female; Fenoterol; Fetal | 2008 |
Comparison of transplacental treatment of fetal supraventricular tachyarrhythmias with digoxin, flecainide, and sotalol: results of a nonrandomized multicenter study.
Topics: Anti-Arrhythmia Agents; Digoxin; Drug Evaluation; Female; Fetal Diseases; Fetal Therapies; Flecainid | 2011 |
Rapid control of foetal supraventricular tachycardia with digoxin and flecainide combination treatment.
Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Atrial Flutter; Digoxin; Drug Therapy, Combination; Echoc | 2012 |
A novel method of fetal cardioversion.
Topics: Administration, Oral; Arrhythmias, Cardiac; Digoxin; Dose-Response Relationship, Drug; Drug Administ | 2013 |
Transplacental flecainide therapy in the treatment of fetal supraventricular tachycardia.
Topics: Adult; Anti-Arrhythmia Agents; Cardiotocography; Electrocardiography; Female; Fetal Diseases; Flecai | 2002 |
Neonatal ECG changes caused by supratherapeutic flecainide following treatment for fetal supraventricular tachycardia.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrocardiography; Female; Fetal Diseases; Flecainid | 2003 |
[Results of prenatal management of fetuses with supraventricular tachycardia. A series of 66 cases].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Flutter; Clinical Protocols; Digoxin; Echocardiography; F | 2003 |
Neonatal flecainide toxicity following supraventricular tachycardia treatment.
Topics: Anti-Arrhythmia Agents; Dobutamine; Enoximone; Female; Fetal Diseases; Flecainide; Humans; Infant, N | 2003 |
[Fetal supraventricular tachyarrhythmias refractory to initial therapy].
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Digoxin; Female; Fetal Diseases; Flecainide; Humans; Male | 2005 |
Flecainide treatment of fetal tachycardia and hydrops fetalis in a twin pregnancy.
Topics: Anti-Arrhythmia Agents; Echocardiography; Female; Fetal Diseases; Flecainide; Humans; Hydrops Fetali | 2006 |
Fetal and maternal magnetocardiography during flecainide therapy for supraventricular tachycardia.
Topics: Anti-Arrhythmia Agents; Diseases in Twins; Electrocardiography; Female; Fetal Diseases; Flecainide; | 2006 |
The effect of flecainide acetate on fetal heart rate variability: a case report.
Topics: Adult; Female; Fetal Diseases; Flecainide; Heart Rate, Fetal; Humans; Pregnancy; Tachycardia, Suprav | 1995 |
Conjugated hyperbilirubinemia in a newborn infant after maternal (transplacental) treatment with flecainide acetate for fetal tachycardia and fetal hydrops.
Topics: Female; Fetal Diseases; Flecainide; Humans; Hydrops Fetalis; Infant; Infant, Newborn; Jaundice, Neon | 1995 |
Management outcome and follow-up of fetal tachycardia.
Topics: Atrial Flutter; Digoxin; Echocardiography; Female; Fetal Diseases; Fetal Heart; Flecainide; Follow-U | 1994 |
Cardioversion of fetal tachyarrhythmia with adenosine.
Topics: Adenosine; Adult; Digoxin; Female; Fetal Diseases; Flecainide; Heart Rate, Fetal; Humans; Infant, Ne | 1994 |
The efficacy of flecainide versus digoxin in the management of fetal supraventricular tachycardia.
Topics: Anti-Arrhythmia Agents; Digoxin; Edema; Female; Fetal Diseases; Flecainide; Humans; Pregnancy; Retro | 1995 |
[Flecaine: drug of choice for supraventricular tachycardias with anasarca. A case report].
Topics: Anti-Arrhythmia Agents; Electrocardiography; Female; Fetal Diseases; Flecainide; Heart Failure; Huma | 1997 |
[European protocol for the management of fetal supraventricular tachycardia. European Association of Pediatric Cardiology].
Topics: Anti-Arrhythmia Agents; Digoxin; Drug Therapy, Combination; Electrocardiography; Female; Fetal Death | 1997 |
Flecainide against fetal supraventricular tachycardia complicated by hydrops fetalis.
Topics: Anti-Arrhythmia Agents; Female; Fetal Diseases; Flecainide; Follow-Up Studies; Humans; Hydrops Fetal | 1998 |
Transplacental flecainide therapy for fetal supraventricular tachycardia in a twin pregnancy.
Topics: Adult; Anti-Arrhythmia Agents; Diseases in Twins; Ethics, Medical; Female; Fetal Diseases; Flecainid | 1999 |
The Mirror syndrome.
Topics: Adult; Anti-Arrhythmia Agents; Female; Fetal Diseases; Flecainide; Humans; Hydrops Fetalis; Pre-Ecla | 2000 |
Digoxin, flecainide, and amiodarone transfer across the placenta and the effects of an elevated umbilical venous pressure on the transfer rate.
Topics: Amiodarone; Anti-Arrhythmia Agents; Area Under Curve; Digoxin; Female; Fetal Diseases; Flecainide; H | 2000 |
[Fetal arrhythmias: diagnosis, prognosis, treatment; apropos of 33 cases].
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Bradycardia; Cardiac Complexes, Premature; Echocardiog | 2000 |
Prenatal diagnosis of the Wolf-Parkinson-White-syndrome by fetal magnetocardiography.
Topics: Adult; Anti-Arrhythmia Agents; Electrocardiography; Female; Fetal Diseases; Flecainide; Humans; Magn | 2001 |
Flecainide in the intrauterine treatment of fetal supraventricular tachycardia.
Topics: Anti-Arrhythmia Agents; Cardiotocography; Digoxin; Female; Fetal Diseases; Flecainide; Humans; Hydro | 2002 |
Treatment of fetal supraventricular tachycardia with flecainide acetate after digoxin failure.
Topics: Adult; Digoxin; Female; Fetal Diseases; Flecainide; Humans; Pregnancy; Tachycardia, Supraventricular | 1992 |
Intermittent fetal tachycardia and fetal hydrops.
Topics: Adult; Female; Fetal Diseases; Flecainide; Humans; Hydrops Fetalis; Pregnancy; Tachycardia, Supraven | 1991 |
Flecainide in the treatment of fetal tachycardias.
Topics: Cardiac Output, Low; Digoxin; Female; Fetal Death; Fetal Diseases; Flecainide; Humans; Pregnancy; Ta | 1991 |
Fetal supraventricular tachycardia treated with flecainide acetate.
Topics: Adult; Female; Fetal Diseases; Fetal Heart; Flecainide; Humans; Infant, Newborn; Male; Pregnancy; Ta | 1991 |
Maternal administration of flecainide to terminate and suppress fetal tachycardia.
Topics: Female; Fetal Diseases; Flecainide; Humans; Maternal-Fetal Exchange; Pregnancy; Tachycardia | 1988 |
Encainide for resistant supraventricular tachycardia in children: follow-up report.
Topics: Administration, Oral; Adolescent; Anilides; Anti-Arrhythmia Agents; Child; Child, Preschool; Drug Th | 1988 |
Direct intrauterine fetal treatment of fetal tachyarrhythmia with severe hydrops fetalis by antiarrhythmic drugs.
Topics: Anti-Arrhythmia Agents; Female; Fetal Diseases; Flecainide; Humans; Hydrops Fetalis; Medigoxin; Preg | 1988 |